惠立妥膜衣錠

国家: 台湾

语言: 中文

来源: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

有效成分:

TENOFOVIR DISOPROXIL FUMARATE

可用日期:

香港商吉立亞醫藥有限公司台灣分公司 臺北市信義區松仁路32號10樓之1、36號10樓之1 (54376860)

ATC代码:

J05AF07

药物剂型:

膜衣錠

组成:

TENOFOVIR DISOPROXIL FUMARATE (0818003510) Equivalent to tenofovir disoproxil 245mg

每包单位数:

塑膠瓶裝

类:

製　劑

处方类型:

須由醫師處方使用

厂商:

GILEAD SCIENCES INC. 333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA(CA) 94404, USA US

治疗领域:

tenofovir disoproxil

疗效迹象:

1.Viread適用於與其他抗反轉錄病毒藥物合併使用於成人HIV-1感染之治療。2.Viread適用於與其他抗反轉錄病毒藥物併用，治療對NRTI產生抗藥性，或因毒性反應無法使用第一線藥物治療之HIV-1感染的12歲(含)至18歲小兒患者。3.Viread用於治療具有病毒複製及活動性肝臟發炎証據之慢性B型肝炎的成人與12歲及以上小兒患者。

產品總結:

有效日期: 2027/08/31; 英文品名: Viread Tablets

授权日期:

2007-08-31

资料单张

5%
5%
d
18%
12%
a.
b.
c.
d.
Stavudine
40%
9%
VIREAD
19%
1%
VIREAD
Stavudine
3
3
4
3
903
VIREAD
≥
1%
3-4
0
144
VIREAD+3TC+EFV
d4T+3TC+EFV
N=299
N=301
≥
3
36%
42%
> 240 mg/dL
19%
40%
> 990 U/L
；
> 845 U/L
12%
12%
> 175 U/L
9%
8%
AST
> 180 U/L
；
> 170 U/L
5%
7%
ALT
> 215 U/L
；
> 170 U/L
4%
5%
> 100 RBC/HPF
7%
7%
< 750/mm
3
3%
1%
> 750 mg/dL
1%
9%
934
934
511
VIREAD+EMTRIVA
®
efavirenz N=257
zidovudine/lamivudine
efavirenz N=254
4
903
HIV-1
144
VIREAD+
lamivudine+efavirenz
BMD
-2.2%
3.9
stavudine+lamivudine+efavirenz
-1.0% 4.6
BMD
VIREAD
-2.8% 3.5
stavudine
-2.4% 4.5
BMD
24-
48
144
28%
VIREAD
21%
stavudine
BMD
5%
BMD
7%
4
VIREAD
6
stavudine
stavudine
VIREAD
酶
肽
肽
1,25
D
；
酶
5.6
4
934
5%
a
2
4
≥
0
144
VIREAD
b
+FTC+EFV
AZT/3TC+EFV
N=257
N=254
9%
5%
9%
7%
2%
5%
9%
8%
8%
4%
8%
5%
5%
3%
6%
5%
8%
7%
9%
7%
5%
7%
c
7%
9%
a.
b.
96
144
TRUVADA
efavirenz
VIREAD+
EMTRIVA
efavirenz
c.
5
5
934
≥
1%
0
144
VIREAD
a
+FTC+EFV
AZT/3TC+EFV
N=257
N=254
≥
3
30%
26%
> 240 mg/dL
22%
24%
> 990 U/L
> 845 U/L
9%
7%
> 175 U/L
8%
4%
> 550 U/L
1%
0%
AST
> 180 U/L
> 170 U/L
3%
3%
ALT
> 215 U/L
> 170 U/L
2%
3%
< 8.0 mg/dL
0%
4%
> 250 mg/dL
2%
1%
> 75 RBC/HPF
3%
2%
≥
3+
< 1%
1%
< 750/mm
3
3%
5%
> 750 mg/dL
4%
2%
a.
96
144
TRUVADA
efavirenz
VIREAD+
EMTRIVA
efavirenz
1%
907
6
907
48
6
907
≥
3%
a
2
4
0
48
VIREAD
N=368
0-24
N=182
0-24
VIREAD
N=368
0-48
VIREAD
N=170
24-48
7%
6%
11%
1%
7%
7%
12%
4%
5%
5%
8%
2%
4%
3%
7%
6%
3%
3%
4%
2%
3%
1%
3%
2%
2%
2%
4%
2%
11%
10%
16%
11%
8%
5%
11%
7%
4%
1%
7%
5%
3%
2%
4%
1%
3%
2%
4%
2%
3%
1%
4%
1%
2%
0%
3%
2%
4%
3%
8%
4%
3%
2%
4%
4%
b
3%
3%
5%
2%
1%
3%
3%
1%
c
5%
4%
7%
1%
3%
2%
3%
1%
3%
3
%
4%
1%
2%
1%
4%
2%
a.
b.
c.
VIREAD
7
3
4
7
907
VIREAD
≥
1%
3-4
0
48
VIREAD
N=368
0-24
N=182
0-24
VIREAD
N=368
0-48
VIREAD
N=170
24-48
≥
3
25%
38%
35%
34%
> 750 mg/dL
8%
13%
11%
9%
> 990U/L
> 845 U/L
7%
14%
12%
12%
> 175 U/L
6%
7%
7%
6%
≥
3+
3%
3%
3%
2%
AST
> 180 U/L
> 170 U/L
3%
3%
4%
5%
ALT
> 215 U/L
> 170 U/L
2%
2%
4%
5%
> 250 U/L
2%
4%
3%
3%
< 750/mm
3
1%
1%
2%
1%
HIV-1
12
12
87
48
VIREAD N=45